Correction to: Longitudinal Characterization of Autoantibodies to the Thyrotropin Receptor (TRAb) During Alemtuzumab Therapy: Evidence that TRAb May Precede Thyroid Dysfunction by Many Years by Muller I,Willis M,Healy S,Nasser T,Loveless S,Butterworth S,Zhang L,Draman MS,Taylor PN,Robertson N,Dayan CM,and Ludgate ME. Thyroid 2018;28:1682–1693. DOI: 10.1089/thy.2018.0232

In the December 2018 issue of Thyroid (vol. 28, no. 12; 1682–1693) the article entitled “Longitudinal Characterization of Autoantibodies to the Thyrotropin Receptor (TRAb) During Alemtuzumab Therapy: Evidence that TRAb May Precede Thyroid Dysfunction by Many Years” by Muller et al. requires correction.

In the published title, the second instance of TRAb was incorrectly defined.

The title read:

Longitudinal Characterization of Autoantibodies to the Thyrotropin Receptor During Alemtuzumab Therapy: Evidence that the Thyrotropin Receptor May Precede Thyroid Dysfunction by Many Years

It has been revised to:

Longitudinal Characterization of Autoantibodies to the Thyrotropin Receptor (TRAb) During Alemtuzumab Therapy: Evidence that TRAb May Precede Thyroid Dysfunction by Many Years

The online version has been corrected to reflect this.